Abstract
Piperacillin/tazobactam (YTR 830; CL-298,741) was tested against fresh and stock clinical isolates of Gram-negative bacilli, as well as against Gram-negative bacilli that had stably derepressed Class I beta-lactamases or that were hyperproductive of non-Class I beta-lactamases. Of 63 clinical isolates of the Enterobacteriaceae with ticarcillin (plus clavulanate) minimum inhibitory concentrations (MICs) of ⩾128 μg/ml, 16 had piperacillin/tazobactam MICs of ⩽ 16 2 μ g/ml . Of 48 clinical isolates of Pseudomonas spp. with ticarcillin (plus clavulanate) MICs of ⩾128 μg/ml, 35 had piperacillin/tazobactam MICs of ⩽ 64 8 μ g/ml . Tazobactam generally reduced piperacillin MICs by two- to ⩾eightfold against stably derepressed mutants for Class I beta-lactamases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
